Who is this study for: Adult patients with Non-Melanoma Skin Cancer (NMSC) or Lymphoma
Enrollment Status: Recruiting
Publish Date: November 15, 2022
Intervention Type: Biological, Other
Study Drugs: NivolumabTalimogene Laherparevec
Study Phase: Phase 2
Summary: This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate...